Carmat (Alternext: ALCAR) was co-founded in 2008 by Truffle Capital, EADS and Professor Carpentier with the support of Bpifrance. Carmat has developed a completely implantable artificial heart, including right and left ventricles and whose design is aimed at being as close as possible to a human heart. Cardiovascular illnesses currently affect more than 100 million patients in developed countries and are the main cause of death in the world.
Carmat was listed on Alternext in July 2010.
Dr Philippe Pouletty is a Board member.